期刊
LANCET CHILD & ADOLESCENT HEALTH
卷 6, 期 11, 页码 820-828出版社
ELSEVIER SCI LTD
DOI: 10.1016/S2352-4642(22)00212-7
关键词
-
类别
资金
- US National Institute on Alcohol Abuse and Alcoholism [K24AA026876-01]
- US National Institute on Drug Abuse [F31DA054701]
There has been a global increase in the use of electronic nicotine delivery systems, cannabis, and prescription drugs among adolescents, which are collectively called ECPO. The nature of ECPO use makes it difficult to detect, posing challenges for screening, prevention, and intervention. This article reviews empirical data on the effects of ECPO use in adolescents and provides concrete approaches for screening and intervention.
There has been a global surge in adolescents' use of electronic nicotine delivery systems (vaping), cannabis (vaped and edible), and prescription opioids, collectively termed ECPO. The nature of ECPO use can make it difficult to detect due to few obvious immediate physical and behavioural signs, as well as subtle long-term effects that allow adolescents to transition from initial exploration into hazardous ECPO use without easy detection by care providers. Here, we address the nature of the presentation of ECPO use in adolescents (roughly age 13-18 years), including challenges in detecting use and related complications, which affect screening, prevention, and intervention. We begin by reviewing empirical data on these difficult to detect effects in adolescents, including acute effects at cellular and neural levels and long-term neurocognitive and developmental changes that precede outwardly detectable physical signs. We then provide concrete approaches for providers to screen for ECPO use in adolescents even in the absence of overt physical and behavioural symptoms. Finally, we conclude with direct practice recommendations for prevention and intervention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据